Latham-Led Vax Developer Launches Plans For $175M IPO
Vaccine developer HilleVax Inc. on Monday set a price range on an estimated $175 million initial public offering, potentially braving waters in a cold IPO market, advised by Latham & Watkins...To view the full article, register now.
Already a subscriber? Click here to view full article